Navigation Links
Romark Announces Clinical Trial Results for New Influenza Drug Presented at IDSA Meeting 2011
Date:10/21/2011

Jason Haffizulla, Harvey Resnick, Aaron Hartman, Stefan Comhaire, Maria Carríon, Matthew Bardin. Presentation Number LB-35, Session 182a: Late Breaker Oral Abstracts - Clinical Virology and Treatment. Saturday, October 22, 2011, 6:30 PM.

About the US Clinical Trial

The clinical trial was conducted in 74 outpatient primary care centers throughout the United States during the 2010-2011 flu season.  624 patients, 12 to 65 years of age, with influenza symptoms were enrolled in the study within 48 hours of symptom onset and received treatment with 300 mg NTZ, 600 mg NTZ or placebo twice daily for 5 days.  Patients who received an influenza vaccine after August 1, 2010 and patients at risk of complications of influenza based upon CDC or IDSA criteria were excluded from participation in the trial. The study was designed according to FDA Guidance and consistent with prior clinical trials of Tamiflu® and Relenza®. The primary efficacy endpoint of the study was time from first dose to alleviation of symptoms (all symptoms absent or mild and remain so for 24 hours).  

Two hundred and fifty-seven (257) of the 624 patients enrolled in the study (41%) had laboratory confirmed influenza infection by RT-PCR or viral culture at baseline. Approximately half of the influenza-infected patients enrolled in the US clinical trial were infected with influenza A subtype H1N1 ("swine flu") with approximately 30% being infected with influenza B and 20% with influenza A subtype H3N2. The trial achieved its primary endpoint showing that influenza-infected patients treated with NT-300 administered 600 mg twice daily for five days experienced statistically significant reduction in time from beginning treatment to alleviation of flu symptoms compared to influenza-infected patients receiving the placebo (P=0.008). Median time to alleviation of symptoms was 95.5 hours for the 600 mg dose group compared to 109.1 hours for the 300 mg do
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
5. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
6. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
7. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
8. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
9. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
10. Romark Announces Data Presented at AASLD Meeting 2010
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
(Date:7/24/2014)...  Restore Health, a leading personalized medicine company ... it is now offering pharmacogenetics testing that provides ... upon their particular genetic makeup. Comprehensive medication management ... a patient,s genetics and their entire drug regimen.  ... this new service to healthcare providers and their ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, announced today that the Company,s ... the position of President and Chief Executive Officer, effective ... Chief Executive Officer in May 2010, and prior thereto ...
... Inc., today reported positive clinical trial results on ... inhalation), an antibiotic that is entering Phase III ...  The results demonstrate significant clinical benefit and complete ... of lung infections due to the bacterium, ...
Cached Medicine Technology:PharmAthene Appoints Eric I. Richman President and Chief Executive Officer 2PharmAthene Appoints Eric I. Richman President and Chief Executive Officer 3ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 2ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 3ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 4ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 5
(Date:7/24/2014)... The report, “Content Delivery Networks (CDN) Market”, defines ... with an in-depth analysis and forecasting of revenues. ... this market with insights on trends, opportunities, and ... 36 figures spread through 157 pages and in-depth ... http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . , Early buyers will ...
(Date:7/24/2014)... Four Seasons Resort Maui at Wailea ... million renovation of the famed Maile suite and the ... in time to welcome summer guests vacationing to this ... the internationally-acclaimed BraytonHughes Design Studios, San Francisco and London, ... the largest in Hawaii—received a complete re-envisioning. No stranger ...
(Date:7/24/2014)... 2014 The federal judge overseeing ... in the U.S. District Court, District of Massachusetts, ... medical information covered by the federal Health Insurance ... 16th Order, U.S. District Judge Douglas P. Woodlock ... Care the right to receive HIPAA- protected information. ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Just as ... they must consider their own financial and marketing strength ... weak marketing campaigns to the next level by using ... Call Center, IVR, Voice Broadcast, Call Tracking and ... 98% open rate, text messages are quickly become integral ...
(Date:7/24/2014)... 24, 2014 In a July 9th article ... founder of Lotus Blossom Consulting LLC , was quoted ... Three Ways to Cut the High Cost of Infertility . ... costs is to maximize your chance of success from the ... a clinic. , “I am always happy to talk ...
Breaking Medicine News(10 mins):Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3
... 3 The National,Fibromyalgia Association today announced that ... III, will be its designated spokeswoman to,help raise ... illness that experts believe affects up to 10 ... Mrs. Bremer was diagnosed with fibromyalgia 25 ...
... join Terrence Howard, Natalie, Maines and Abigail Breslin to ... ... SAN FRANCISCO, Oct. 3 Gap is proud to,introduce ... to help eliminate AIDS in Africa. Captured by acclaimed,photographer Annie ...
... /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. (TSX: PMD; ... on the,company,s 510(k) application to the US Food ... On Wednesday, October 3, 2007, Dr. Brent ... present at BioContact Quebec, a leading,annual biopharmaceutical conference. ...
... New research from the Howard Florey Institute in Melbourne ... cause epilepsy in infants. , Infants are more susceptible ... rapid rate, making their brain cells excitable. Their neurons ... cells, which can disrupt normal brain activity and results ...
... Laboratory (EMBL), the University of Helsinki, Finland, the ... officially launch their new Nordic EMBL Partnership for ... and collaborations between the partners and will facilitate ... for an initial period of five years. ...
... spur these outbursts , WEDNESDAY, Oct. 3 (HealthDay News) ... problems can help prompt dogs to bite children, a ... Pennsylvania looked at 111 cases involving 103 dogs that ... clinic over four years. , "Guarding of resources and ...
Cached Medicine News:Health News:Frances Winfield Bremer, Wife of Ambassador L. Paul Bremer, III, to Become Spokeswoman for the National Fibromyalgia Association 2Health News:Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED 2Health News:Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED 3Health News:Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED 4Health News:PreMD Inc. Provides Corporate Update 2Health News:PreMD Inc. Provides Corporate Update 3Health News:Research shows how genetic mutation causes epilepsy in infants 2Health News:EMBL reaches north 2Health News:Medical, Behavioral Woes Can Drive Dogs to Bite 2
... for strength and durability. Four 64 mirrors ... minimal lens rotation. Choice of three handles ... Small diameter contact surface allows static or ... polymer coating protects mirrors and is compatible ...
... Three mirrors of 64, 67 ... diameter contact surface for use ... be viewed through the central ... polymer coating protects mirrors and ...
Small size gonio lens with one 62 mirror. Compact knurled ring simplifies 360 viewing of the anterior chamber angle....
Lacrimal cannula blunt tip with 0.3 mm side port, straight....
Medicine Products: